Skip to Content
Merck
  • ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment.

ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment.

Nature communications (2020-07-17)
Chi-Lam Au-Yeung, Tsz-Lun Yeung, Abhinav Achreja, Hongyun Zhao, Kay-Pong Yip, Suet-Ying Kwan, Michaela Onstad, Jianting Sheng, Ying Zhu, Dodge L Baluya, Ngai-Na Co, Angela Rynne-Vidal, Rosemarie Schmandt, Matthew L Anderson, Karen H Lu, Stephen T C Wong, Deepak Nagrath, Samuel C Mok
ABSTRACT

Advanced ovarian cancer usually spreads to the omentum. However, the omental cell-derived molecular determinants modulating its progression have not been thoroughly characterized. Here, we show that circulating ITLN1 has prognostic significance in patients with advanced ovarian cancer. Further studies demonstrate that ITLN1 suppresses lactotransferrin's effect on ovarian cancer cell invasion potential and proliferation by decreasing MMP1 expression and inducing a metabolic shift in metastatic ovarian cancer cells. Additionally, ovarian cancer-bearing mice treated with ITLN1 demonstrate marked decrease in tumor growth rates. These data suggest that downregulation of mesothelial cell-derived ITLN1 in the omental tumor microenvironment facilitates ovarian cancer progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Omentin Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Lactoferrin from human milk, powder, BioReagent, suitable for cell culture